Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naive Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.

ABSTRACT: AIMS:To investigate the efficacy and safety of insulin degludec/liraglutide (IDegLira) compared with its individual components in Japanese people with type 2 diabetes (T2D) uncontrolled on an oral antidiabetic drug (OAD). MATERIALS AND METHODS:This 52-week, open-label, multicentre, treat-to-target trial randomized participants (n = 819) 1:1:1 to IDegLira, liraglutide 1.8 mg or degludec, as add-on to their pre-trial OAD. The maximum IDegLira dose was 50 dose steps (50?U degludec/1.8 mg liraglutide), there was no maximum dose for degludec, and both were titrated based on individual blood glucose measurements. RESULTS:After 52?weeks, glycated haemoglobin (HbA1c) decreased by 26?mmol/mol with IDegLira vs 20?mmol/mol with degludec and liraglutide: estimated treatment differences were -6.91?mmol/mol (95% confidence interval [CI] -8.18; -5.64) and -5.30?mmol/mol (95% CI -6.58; -4.03), confirming non-inferiority of IDegLira to degludec and superiority of IDegLira to liraglutide (P?

SUBMITTER: Kaku K 

PROVIDER: S-EPMC6899795 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature